keyword
MENU ▼
Read by QxMD icon Read
search

anti-tnf

keyword
https://www.readbyqxmd.com/read/27933686/risk-of-incident-mycobacterium-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-a-nationwide-population-based-study-in-south-korea
#1
S N Hong, H J Kim, K H Kim, S-J Han, I M Ahn, H S Ahn
BACKGROUND: The low incidence of Mycobacterium tuberculosis infection and lack of adequate controls have prevented researchers from estimating tuberculosis (TB) risk in inflammatory bowel disease (IBD) patients. AIM: To evaluate the risk of incident TB among IBD patients. METHODS: Using the 2011-2013 data of the South Korean National Health Insurance (NHI) system, we calculated the incidence rates (IRs), standardised incidence ratio (SIR) and number needed to screen (NNS) for incident TB in IBD patients compared to the general population in terms of subtype, age, gender and IBD medications...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27933472/tumor-necrosis-factor-alpha-inhibitors-did-not-influence-postoperative-morbidity-after-elective-surgical-resections-in-crohn-s-disease
#2
Paulo Gustavo Kotze, Mansur Paulo Saab, Bárbara Saab, Lorete Maria da Silva Kotze, Marcia Olandoski, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Maria de Lourdes Setsuko Ayrizono, Daniela de Oliveira Magro, Claudio Saddy Rodrigues Coy
BACKGROUND: The real impact of anti-tumor necrosis alpha (TNF) therapy in postoperative complications after intestinal resections in Crohn's disease (CD) still needs to be determined. AIMS: To compare the postoperative complication rates after elective intestinal resections in CD patients, with or without previous exposure to anti-TNF therapy. METHODS: This was a retrospective and observational study, with elective intestinal resections for CD (emergency procedures were excluded)...
December 8, 2016: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27932278/patient-perceived-flares-in-rheumatoid-arthritis-a-sub-analysis-of-the-strass-treatment-tapering-strategy-trial
#3
Agnès Portier, Laure Gossec, Florence Tubach, Toni Alfaiate, Thao Pham, Alain Saraux, Martin Soubrier, Thierry Schaeverbeke, Jean-Francis Maillefert, Xavier Mariette, David Hajage, Bruno Fautrel
OBJECTIVES: Patient's and physician's perspective can differ in rheumatoid arthritis (RA). The aim was to define the concept of patient-reported flares. METHODS: Post-hoc analysis of a randomized controlled trial of a step-down strategy in RA patients treated with anti-TNF, in DAS28-remission for ≥6 months, randomized to either "spacing" or "maintaining" anti-TNF. The occurrence of patient-reported flares (PRF) was evaluated every 3 months for 18 months by: "Over the last 3 months, did you experience symptoms suggestive of disease exacerbation?"...
December 5, 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/27931132/guillain-barr%C3%A3-syndrome-during-adalimumab-therapy-for-crohn%C3%A2-s-disease-coincidence-or-consequence
#4
Guilherme Grossi Lopes Cançado, Eduardo Garcia Vilela
We report the case of a 64-year-old patient diagnosed with extensive ileal Crohn´s disease who developed Guillain-Barré syndrome after starting biological therapy with adalimumab. Neurologic involvement associated with inflammatory bowel diseases is recognized as an extra-intestinal manifestation. After the breakthrough of antitumor necrosis factor alpha (anti-TNF-α) agents, an increasing number of cases of acute inflammatory demyelinating polyneuropathies have been reported; however, only one case has been described in a patient with Crohn´s disease...
December 8, 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27930541/cytotoxic-th1-and-th17-cells-infiltrate-the-intestinal-mucosa-of-behcet-patients-and-exhibit-high-levels-of-tnf-%C3%AE-in-early-phases-of-the-disease
#5
Giacomo Emmi, Elena Silvestri, Chiara Della Bella, Alessia Grassi, Marisa Benagiano, Fabio Cianchi, Danilo Squatrito, Luca Cantarini, Lorenzo Emmi, Carlo Selmi, Domenico Prisco, Mario Milco D'Elios
BACKGROUND: Gastrointestinal involvement is one of the most serious in Behçet disease, potentially leading to severe complications. Aim of this study was to investigate at mucosal level the T-cell responses in Behçet patients with early intestinal involvement. METHODS: We isolated T cells from intestinal mucosa of 8 patients with intestinal symptoms started within 6 months. T lymphocytes were cloned and analyzed for surface phenotype and cytokines production. RESULTS: We obtained 382 T-cell clones: 324 were CD4+ and 58 were CD8+...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27928154/rheumatoid-arthritis-anti-tnf-agents-go-head-to-head
#6
Sarah Onuora
No abstract text is available yet for this article.
December 8, 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27924646/influence-of-anti-tnf-immunogenicity-on-safety-in-rheumatic-disease-a-narrative-review
#7
Andrea Matucci, Daniele Cammelli, Fabrizio Cantini, Delia Goletti, Valentina Marino, Giuseppe Maria Milano, Raffaele Scarpa, Giuliano Tocci, Enrico Maggi, Alessandra Vultaggio
Tumor necrosis factor-alpha (TNF-α) antagonists have been shown to be effective in the treatment of chronic inflammatory rheumatic conditions. The use of anti-TNF agents, combined with improved diagnosis, aggressive regimens and regular monitoring, have substantially improved patient outcomes. However, all biological agents are immunogenic, resulting in the formation of anti-drug antibodies (ADAs), which can neutralize drug activity leading to loss of response and potential relapse. In addition, ADAs can also cause serious adverse events such as infusion hypersensitivity reactions...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27924645/cardiovascular-outcomes-and-tumour-necrosis-factor-antagonists-in-chronic-inflammatory-rheumatic-disease-a-focus-on-rheumatoid-arthritis
#8
Giuliano Tocci, Delia Goletti, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Fabrizio Cantini, Raffaele Scarpa
Many chronic rheumatic diseases have an inflammatory etiology, leading to accelerated atherosclerosis and increased occurrence of vascular diseases. In rheumatoid arthritis (RA), a reduction in cardiovascular (CV) events has been reported under treatments reducing systemic inflammation. Areas covered: Given the central role of tumour necrosis factor alpha (TNFα) in chronic inflammatory conditions and in atherosclerosis, it has been suggested that TNFα-antagonists may reduce CV risk and mortality. Although there are no randomized controlled or head-to-head trials investigating the effect of specific anti-TNF-agents on CV outcomes, observational cohort studies, national registry data, and meta-analyses in RA have reported improved CV outcomes with anti-TNF therapy...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27924644/risk-of-malignancies-using-anti-tnf-agents-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-a-systematic-review-and-meta-analysis
#9
Stefanos Bonovas, Silvia Minozzi, Theodore Lytras, Marien González-Lorenzo, Valentina Pecoraro, Silvia Colombo, Ilaria Polloni, Lorenzo Moja, Michela Cinquini, Valentina Marino, Delia Goletti, Andrea Matucci, Giuliano Tocci, Giuseppe Maria Milano, Raffaele Scarpa, Fabrizio Cantini
Malignancies have been reported in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, treated with anti-tumour necrosis factor (anti-TNF) agents. Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) to determine the effect of anti-TNF agents on the occurrence of cancer (any type). Literature databases were searched up to May 2014 to identify relevant studies that evaluated adalimumab, certolizumab, etanercept, golimumab, or infliximab, compared with placebo or no treatment...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27924643/risk-of-infections-using-anti-tnf-agents-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-a-systematic-review-and-meta-analysis
#10
Silvia Minozzi, Stefanos Bonovas, Theodore Lytras, Valentina Pecoraro, Marien González-Lorenzo, Anan Judina Bastiampillai, Eugenia Maria Gabrielli, Andrea Carlo Lonati, Lorenzo Moja, Michela Cinquini, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Giuliano Tocci, Raffaele Scarpa, Delia Goletti, Fabrizio Cantini
Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection)...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27917631/-15-years-experience-with-biological-therapy-of-inflammatory-rheumatic-diseases-in-czech-national-register-attra
#11
Karel Pavelka, Liliana Šedová, Karel Hejduk, Ladislav Dušek
The publication is summarizing application of biological DMARDs in autoimmune inflammatory rheumatic diseases.Up to now conventional therapy, which for example in rheumatoid arthritis was application of methotrexate (MTx) in combination with glucocorticoids, was effective, but the remission as a target was achieved in small proportion of patients and also there was little effect on structural progression of diseases. Biological therapy was great advance because response was achieved in ¾ patients who failed MTx...
2016: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/27914593/systemic-and-localized-infection-by-candida-species-in-patients-with-rheumatic-diseases-receiving-anti-tnf-therapy
#12
Nadia E Aikawa, Daniela T A Rosa, Gilda M B Del Negro, Julio C B Moraes, Ana C M Ribeiro, Carla Gonçalves Saad, Clovis A Silva, Eloisa Bonfá
OBJECTIVE: To evaluate the prevalence of systemic and localized infection by Candida species and its possible association with demographic, clinical and laboratory manifestations and therapy in patients with rheumatic diseases taking TNF blockers. METHODS: Consecutive patients with rheumatic diseases receiving anti-TNF agents were included. The following risk factors up to four weeks prior to the study were analyzed: use of antibiotics, immunosuppressant drugs, hospitalization and invasive procedures...
November 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27914136/physicians-should-provide-shared-decision-making-for-anti-tnf-therapy-to-inflammatory-bowel-disease-patients
#13
Jae Myung Cha, Dong Il Park, Sang Hyoung Park, Jeong Eun Shin, Wan Soo Kim, Suk Kyun Yang
Shared decision-making may increase the effectiveness of inflammatory bowel disease (IBD) treatment, as different anti-tumor necrosis factor (anti-TNF) administrations may have different effects on the quality of life (QOL). Patient preference is integral to the selection of anti-TNFs and their routes of administration, however, previous studies on the patient preference to anti-TNFs are inconsistent and limited. We evaluated the predictive factors for preferences to anti-TNF administrations in IBD patients between March and August in 2015...
January 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/27913060/outcome-of-pregnancy-and-neonatal-complications-with-anti-tumor-necrosis-factor-%C3%AE-use-in-females-with-immune-mediated-diseases-a-systematic-review-and-meta-analysis
#14
REVIEW
Fukiko Komaki, Yuga Komaki, Dejan Micic, Akio Ido, Atsushi Sakuraba
BACKGROUND: Immune mediated diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), and inflammatory bowel disease (IBD) commonly affect young and adolescent females. Anti-tumor necrosis factor (TNF)-α agents are increasingly used to treat these conditions, but their safety during pregnancy remains unclear. OBJECTIVES: To evaluate the risk of pregnancy related outcomes in patients with various immune mediated diseases treated with anti-TNF-α agents...
November 29, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27908311/obesity-decreases-clinical-efficacy-and-levels-of-adalimumab-in-patients-with-ankylosing-spondylitis
#15
José Rosas, Francisca Llinares-Tello, José Miguel Senabre-Gallego, Xavier Barber-Vallés, Gregorio Santos-Soler, Esteban Salas-Heredia, Ana Pons Bas, Catalina Cano Pérez, Mario García-Carrasco
OBJECTIVES: Obesity can be a factor that affects response to anti-TNF drugs. However, studies on patients with ankylosing spondylitis (AS) are rare. We aimed to determine whether obesity affects serum levels of adalimumab (ADL), and immunogenicity and clinical efficacy of the drug in patients with AS. METHODS: A cross-sectional study on 57 patients with axial AS receiving ADL was conducted. They received DMARD per standard of care at their rheumatologist's discretion...
November 13, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27908307/evolution-of-imaging-findings-laboratory-and-functional-parameters-in-rheumatoid-arthritis-patients-after-one-year-of-treatment-with-anti-tnf-%C3%AE-agents
#16
Efstathios E Detorakis, Eleftherios Magkanas, Ismini Lasithiotaki, Prodromos Sidiropoulos, Dimitrios T Boumpas, Nicholas Gourtsoyiannis, Katerina Antoniou, Maria Raissaki
OBJECTIVES: To investigate the efficacy and safety of anti-TNF-α agent treatment compared to non-biologic DMARDs in rheumatoid arthritis patients. METHODS: 82 consecutive patients, 29 males, 53 females, aged 42-79, diagnosed with RA and suitable for anti-TNF-α treatment composed two study groups: 42 with pre-existing rheumatoid arthritis-related interstitial lung disease (RA-ILD) and 40 without RA-ILD. Respective control groups consisted of 44 patients with pre-existing RA-ILD and 44 patients without RA-ILD, treated with non-biologic DMARDs...
October 27, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27908303/dna-damage-increase-in-peripheral-neutrophils-from-patients-with-rheumatoid-arthritis-is-associated-with-the-disease-activity-and-the-presence-of-shared-epitope
#17
Gustavo Martelli-Palomino, Adriana B Paoliello-Paschoalato, Janaina C O Crispim, Diane M Rassi, Rene D Oliveira, Paulo Louzada, Yara Maria Lucisano-Valim, Eduardo A Donadi
OBJECTIVES: Neutrophils play a major role in rheumatoid arthritis (RA) pathogenesis. We aimed to evaluate if neutrophil DNA damage in RA patients is associated with the disease activity, autoantibodies status, carriage of the RA shared epitope (SE) and treatment. METHODS: DNA damage was assessed by alkaline comet assay in peripheral blood (77 patients and 55 healthy controls) and in 10 RA synovial fluid neutrophils. Evaluation of the respiratory burst of 30 patients with RA and 30 healthy controls was done...
November 14, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27908288/granulocyte-macrophage-colony-stimulating-factor-receptor-%C3%AE-expression-and-its-targeting-in-antigen-induced-arthritis-and-inflammation
#18
Andrew D Cook, Cynthia Louis, Matthew J Robinson, Reem Saleh, Matthew A Sleeman, John A Hamilton
BACKGROUND: Blockade of granulocyte macrophage colony-stimulating factor (GM-CSF) and its receptor (GM-CSFRα) is being successfully tested in trials in rheumatoid arthritis (RA) with clinical results equivalent to those found with neutralization of the current therapeutic targets, TNF and IL-6. To explore further the role of GM-CSF as a pro-inflammatory cytokine, we examined the effect of anti-GM-CSFRα neutralization on myeloid cell populations in antigen-driven arthritis and inflammation models and also compared its effect with that of anti-TNF and anti-IL-6...
December 1, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27902515/comparison-of-health-related-quality-of-life-and-disability-in-ulcerative-colitis-patients-following-restorative-proctocolectomy-with-ileal-pouch-anal-anastomosis-versus-anti-tumor-necrosis-factor-therapy
#19
Sara van Gennep, Saloomeh Sahami, Christianne J Buskens, Gijs R van den Brink, Cyriel Y Ponsioen, André D'Hoore, Anthony de Buck van Overstraeten, Gert van Assche, Marc Ferrante, Séverine Vermeire, Willem A Bemelman, Geert R A M D'Haens, Mark Löwenberg
BACKGROUND AND AIMS: Health-related quality of life (HRQL) and disability were compared in ulcerative colitis (UC) patients who underwent restorative proctocolectomy versus patients who received treatment with anti-tumor necrosis factor (anti-TNF) agents. PATIENTS AND METHODS: UC patients who underwent restorative proctocolectomy or started anti-TNF treatment between January 2010 and January 2015 were included at two tertiary referral centers. A matched cohort was created using propensity score matching for the covariates disease duration, Montreal classification, age, and sex...
November 29, 2016: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27895418/molecular-mechanism-of-action-of-anti-tumor-necrosis-factor-antibodies-in-inflammatory-bowel-diseases
#20
REVIEW
Ulrike Billmeier, Walburga Dieterich, Markus F Neurath, Raja Atreya
Anti-tumor necrosis factor (TNF) antibodies are successfully used in the therapy of inflammatory bowel diseases (IBD). However, the molecular mechanism of action of these agents is still a matter of debate. Apart from neutralization of TNF, influence on the intestinal barrier function, induction of apoptosis in mucosal immune cells, formation of regulatory macrophages as well as other immune modulating properties have been discussed as central features. Nevertheless, clinically effective anti-TNF antibodies were shown to differ in their mode-of-action in vivo and in vitro...
November 14, 2016: World Journal of Gastroenterology: WJG
keyword
keyword
34737
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"